The main market opportunities in the eosinophilic esophagitis pipeline include focusing on novel therapeutic approaches, potential development of first-in-class treatments like IRL201104, targeting ...
The global eosinophilic esophagitis drug market size is expected to reach US$ 180.5 million by 2028 according to a new study by Report Ocean. The report “Eosinophilic Esophagitis Drug Market Report, ...
Positive Results from Clinical Pharmacokinetic Study for the Eosinophilic Esophagitis Specific Formulation with the Drug Candidate AQ280Aqilion today announces positive results from the ARIA-2 ...
Everyday Health on MSN
Chronic Idiopathic Urticaria Treatment: Medication, Lifestyle Changes, and More
Treatment for chronic hives lasting at least 6 weeks may include one or more types of medication, as well as certain ...
Sanofi SNY reported third-quarter 2025 adjusted earnings of $1.70 per American depositary share, which beat the Zacks ...
Over the last 13 months, Sanofi and Regeneron have revved up the momentum for Dupixent, gaining three new indications for the ...
Approval Broadens Indication for TEZSPIRE to a Second Disease Characterized by Epithelial-Driven Inflammation THOUSAND OAKS, Calif., Oct. 17, 2025 ...
Zacks Investment Research on MSN
REGN Reports Encouraging Data on Gene Therapy for Genetic Hearing Loss (Revised)
Regeneron Pharmaceuticals, Inc. REGN announced updated data on its investigational gene therapy DB-OTO from the CHORD study.
Detailed price information for Astrazeneca Plc ADR (AZN-Q) from The Globe and Mail including charting and trades.
Health Canada has approved Dupixent® (dupilumab injection) as an add-on maintenance treatment in adult patients with chronic obstructive pulmonary disease (COPD) characterized by raised blood ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback